US FDA approves Abbott's longer-length Esprit for severe PAD

The US FDA has approved Abbott's longer-length Esprit BTK scaffold (76mm) for treating chronic limb-threatening ischaemia, designed to reduce procedural complexity by treating longer lesions with fewer devices. Most below-the-knee lesions in CLTI patients exceed 100mm, making the extended length clinically relevant for workflow efficiency.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.